A structure-based designed small molecule depletes hRpn13^Pru and a select group of KEN box proteins.

ABSTRACT: Proteasome subunit hRpn13 is partially proteolyzed in certain cancer cell types to generate hRpn13^Pru by degradation of its UCHL5/Uch37-binding DEUBAD domain and retention of an intact proteasome- and ubiquitin-binding Pru domain. By using structure-guided virtual screening, we identify an hRpn13 binder (XL44) and solve its structure ligated to hRpn13 Pru by integrated X-ray crystallography and NMR to reveal its targeting mechanism. Surprisingly, hRpn13^Pru is depleted in myeloma cells following treatment with XL44. TMT-MS experiments reveal a select group of off-targets, including PCNA clamp-associated factor PCLAF and ribonucleoside-diphosphate reductase subunit M2 (RRM2), that are similarly depleted by XL44 treatment. XL44 induces hRpn13-dependent apoptosis and also

SUBMITTER: Lu X 

PROVIDER: S-EPMC10954691 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature